Finvest
VKTX Biotechnology · Clinical stage · Obesity drugs · Pre-revenue · Thesis updated July 1, 2026

Obesity hopes meet a new license fight

01 Running thesis

VK2735 carries the stock

Viking is a high-risk biotech built around one big question: can VK2735 become a serious obesity drug? The injectable form is in the VANQUISH Phase 3 program, and the oral form is expected to start Phase 3 in Q4 2026. If the data are strong, Viking could own a valuable obesity asset in one of the largest drug markets in the world.

The bull case is that Viking is moving fast and has more than one shot on goal. VK2735 has both injectable and oral paths. VK3019, its amylin agonist program, began a Phase 1 study in June 2026. That gives Viking a possible next wave in obesity, not only a single GLP-1 and GIP program.

The bear case got worse in April 2026. Ligand Pharmaceuticals sent a notice that it says terminates the TR-Beta license, which includes VK2809 for NASH and VK0214 for X-ALD. Viking says Ligand has no right to do this and plans to defend its rights. Until the dispute is resolved, VK2809 is less of a clean upside option and more of a legal overhang.

Cash is enough for now, but the spend rate is rising fast. Viking reported $150.2 million of Q1 2026 R&D expense and $603.0 million of cash, cash equivalents, and short-term investments at March 31, 2026. Management says that funds operations through at least June 30, 2027, but approval and launch would likely need much more money or a larger partner.

Jun 2026▲Viking began a Phase 1 study of VK3019 in healthy adults with obesity. This adds a new human-stage obesity program beyond VK2735.
Apr 2026▼The Q1 2026 filing added a major legal overhang after Ligand tried to terminate the TR-Beta license covering VK2809. Viking disputes the move, but the asset is now harder to value.
Apr 2026→Viking reported $603.0 million of cash, cash equivalents, and short-term investments and said it was funded through at least June 30, 2027. Q1 R&D expense rose to $150.2 million as Phase 3 obesity trials scaled.
Feb 2026▲Viking said it planned to advance oral VK2735 into Phase 3 after FDA feedback. It also completed the auto-injector bioequivalence work needed for the VANQUISH program.
Feb 2026▲The 2025 Form 10-K confirmed VANQUISH-1 enrollment was complete and clarified timing for oral VK2735 Phase 3. The filing also showed higher 2025 R&D spend as late-stage development scaled.
Oct 2025▲The Q3 2025 filing reflected positive Phase 2 data for oral VK2735. That strengthened the case that Viking could pursue both injectable and oral obesity products.
Jul 2025▲Viking began the pivotal VANQUISH Phase 3 program for injectable VK2735 and confirmed patient dosing had started. This moved the lead obesity asset into the main value-creating stage.
Apr 2025▲Viking signed multi-year manufacturing agreements with CordenPharma for VK2735 supply. This reduced one key execution risk before the pivotal obesity trials.
02 Business model

No sales yet, trial value only

Viking does not have an approved product and does not generate product revenue. Its business is to test drug candidates, raise capital, and try to turn clinical data into either an approved drug, a partnership, or a sale of rights.

That makes the model simple but risky. Cash goes out for research, trials, manufacturing, lawyers, and public company costs. Value comes in only if a program clears clinical and regulatory steps, or if a larger drug company pays to partner with Viking.

VK2735 is the main value driver. The company has also invested in manufacturing capacity with CordenPharma for active ingredient and finished supply. That helps prepare for scale, but it also raises the cost of being wrong.

The Ligand relationship matters because several assets depend on licensed technology. The new dispute shows a weakness in this model: even good clinical data can lose value if the legal right to use an asset is challenged.

03 Product portfolio

Pipeline, not products

Growth engine

VK2735, obesity

VK2735 is a dual GLP-1 and GIP agonist. The injectable version is in the Phase 3 VANQUISH program, and the oral tablet is expected to enter Phase 3 in Q4 2026.

Option

VK2809, NASH

VK2809 is an oral thyroid hormone receptor beta agonist for NASH, a serious liver disease tied to fat buildup and inflammation. It has positive Phase 2b VOYAGE data, but the Ligand license dispute now clouds its value.

Option

VK3019, amylin agonist

VK3019 is a dual amylin and calcitonin receptor agonist, also called a DACRA. Viking started a Phase 1 study in June 2026 to test safety, tolerability, and early weight effects.

Option

VK0214, X-ALD

VK0214 targets X-linked adrenoleukodystrophy, a rare inherited disease. Viking has positive Phase 1b results and intends to seek a partner before more studies.

Option

VK5211, hip fracture recovery

VK5211 is a selective androgen receptor modulator for patients recovering from hip fracture surgery. Viking does not plan to push it forward alone and is seeking a partner.

04 Business segments

One reported segment

Metabolic and endocrine therapy development100%growing fast
All other reported segments0%flat

Viking reports one operating segment: developing therapies for metabolic and endocrine disorders. The company has no commercial revenue, so these shares reflect reported operating structure, not sales mix.

05 Risk factors

What can go wrong

VK2735 Phase 3 miss

High impact · Medium odds

The obesity program drives most of the investment case. If VANQUISH data show weaker weight loss, worse tolerability, or safety issues, Viking would have little revenue support and fewer ways to fund itself on good terms.

We watchTop-line VANQUISH Phase 3 results, dropout rates, side effects, and FDA feedback.

Obesity competition crushes the launch

High impact · High odds

Novo Nordisk and Eli Lilly already sell major obesity drugs and have far larger sales teams, trial budgets, and supply chains. VK2735 must look meaningfully different, such as better weight loss, easier dosing, or better tolerability.

We watchHead-to-head investor comparisons versus Wegovy and Zepbound, plus any pricing or access limits from insurers.

Ligand license loss

High impact · Medium odds

Ligand is trying to terminate the TR-Beta license. If Ligand wins, Viking could lose rights to VK2809 and possibly weaken the value of VK0214. That would remove an important source of pipeline diversity.

We watchCourt filings, settlement news, or any company update on the Master License Agreement.

Cash burn outruns the runway

High impact · Medium odds

Viking spent $150.2 million on R&D in Q1 2026, mainly tied to VK2735 Phase 3 trials. It had $603.0 million in cash, cash equivalents, and short-term investments at March 31, 2026, and expects runway through at least June 30, 2027. A slower trial, added study, or weak market could force a larger and more dilutive financing.

We watchQuarterly cash balance, R&D expense, trial enrollment timing, and any equity offering.

Manufacturing scale-up slips

Medium impact · Medium odds

Obesity drugs require reliable large-scale supply. Viking has agreements with CordenPharma for VK2735 active ingredient and finished product, but it has not launched a drug before. A supply problem could hurt trials, approval prep, or a future launch.

We watchUpdates on CordenPharma capacity, auto-injector use in VANQUISH, and any manufacturing comments in filings.
06 Quick answers

In one breath

Does Viking Therapeutics make money today?

No. Viking is a clinical-stage biotech with no approved products and no commercial product revenue. It funds trials with cash raised from investors.

What is Viking's most important drug?

VK2735 is the key asset. It is being tested for obesity in injectable Phase 3 trials, with an oral Phase 3 program expected to start in Q4 2026.

Why does the Ligand dispute matter?

Ligand is trying to terminate a license that covers the TR-Beta program, including VK2809 for NASH. If Viking loses that dispute, it could lose rights to a major pipeline asset.

How long is Viking funded?

As of March 31, 2026, Viking had $603.0 million in cash, cash equivalents, and short-term investments. Management said that should fund operations through at least June 30, 2027.